Back to results
US 9,175,085 B2Granted
Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist
AssigneeEdimer Pharmaceuticals, Inc.
InventorsPascal Schneider, Christine Kowalczyk
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.
Claims8
A recombinant protein consisting of the amino acid sequence of SEQ ID NO:1.
Dependencies are inferred from the claim text.